HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lipton, R. B. Articles by Schaumburg, H. H. Search for Related Content PubMed PubMed Citation Articles by Lipton, R. B. Articles by Schaumburg, H. H.

Taxol produces a predominantly sensory neuropathy

Department of Neurology, The Albert Einstein College of Medicine, Bronx, NY.(Drs. Lipton, Apfel, Rosenberg, Kaplan, Berger, and Schaumburg)
Department of Oncology (Drs. Dutcher, Einzig, and Wiernik), The Albert Einstein College of Medicine, Bronx, NY.

Taxol, a plant alkaloid with promise as an antineoplastic agent, produced a predominantly sensory neuropathy in 16 of 60 patients treated in two phase I trials. This neuropathy occurred only at taxol doses greater than 200 mg/m². Symptoms typically started 1 to 3 days following treatment, beginning in the hands and feet simultaneously in most patients. Electrophysiologic data suggests both axonal degeneration and demyelination. This previously undefined neurotoxic neuropathy most likely results from taxol's unique ability to produce microtubule aggregation in dorsal root ganglion cells, axons, and Schwann cells.

Address correspondence and reprint requests to Dr. Lipton, Department of Neurology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461.

Received July 25, 1988. Accepted for publication in final form September 21, 1988.

This article has been cited by other articles:

				J. J. Lee and S. M. Swain Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents J. Clin. Oncol., April 1, 2006; 24(10): 1633 - 1642. [Abstract] [Full Text] [PDF]

				S. Mielke, A. Sparreboom, S. M. Steinberg, H. Gelderblom, C. Unger, D. Behringer, and K. Mross Association of Paclitaxel Pharmacokinetics with the Development of Peripheral Neuropathy in Patients with Advanced Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4843 - 4850. [Abstract] [Full Text] [PDF]

				A. A. Argyriou, E. Chroni, A. Koutras, J. Ellul, S. Papapetropoulos, G. Katsoulas, G. Iconomou, and H. P. Kalofonos Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial Neurology, January 11, 2005; 64(1): 26 - 31. [Abstract] [Full Text] [PDF]

				M. S. Wang, A. A. Davis, D. G. Culver, Q. Wang, J. C. Powers, and J. D. Glass Calpain inhibition protects against Taxol-induced sensory neuropathy Brain, March 1, 2004; 127(3): 671 - 679. [Abstract] [Full Text] [PDF]

				H. Openshaw, K. Beamon, T. W. Synold, J. Longmate, N. E. Slatkin, J. H. Doroshow, S. Forman, K. Margolin, R. Morgan, S. Shibata, et al. Neurophysiological Study of Peripheral Neuropathy after High-Dose Paclitaxel: Lack of Neuroprotective Effect of Amifostine Clin. Cancer Res., January 15, 2004; 10(2): 461 - 467. [Abstract] [Full Text] [PDF]

				S. S. Leong, E. H. Tan, K. W. Fong, E. Wilder-Smith, Y. K. Ong, B. C. Tai, L. Chew, S. H. Lim, J. Wee, K. M. Lee, et al. Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2003; 21(9): 1767 - 1774. [Abstract] [Full Text] [PDF]

				M. E. Helgren, K. D. Cliffer, K. Torrento, C. Cavnor, R. Curtis, P. S. DiStefano, S. J. Wiegand, and R. M. Lindsay Neurotrophin-3 Administration Attenuates Deficits of Pyridoxine-Induced Large-Fiber Sensory Neuropathy J. Neurosci., January 1, 1997; 17(1): 372 - 382. [Abstract] [Full Text] [PDF]